A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03583944
- Locations
- 🇮🇳
Sir Ganga Ram Hospital, New Delhi, Delhi, India
🇮🇳Lokmanya Hospital, Pune, Maharashtra, India
🇮🇳Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India
Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
- Conditions
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Eisai Inc.
- Registration Number
- NCT03533361
- Locations
- 🇧🇷
Hospital Sirio Libanes, Sao Paulo, São Paulo, Brazil
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
- Conditions
- Interventions
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 827
- Registration Number
- NCT03517449
- Locations
- 🇺🇸
North Shore University Health System, Evanston, Illinois, United States
🇺🇸Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Study of Lemborexant-Alcohol Interaction in Healthy Subjects
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03483636
- Locations
- 🇨🇦
Syneos Health, Toronto, Ontario, Canada
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03477175
- Locations
- 🇺🇸
Harbor UCLA Medical Center, Torrance, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇩🇪Eisai trial site 2, Essen, Germany
Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT03471871
- Locations
- 🇺🇸
The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸PACT, Glendale, Arizona, United States
🇺🇸Clinilabs Drug Development, New York, New York, United States
Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 326
- Registration Number
- NCT03467152
- Locations
- 🇺🇸
Advanced Research Consultants, Inc., Palm Beach Gardens, Florida, United States
🇺🇸Columbia University, New York, New York, United States
🇺🇸Neurological Associates of Albany, PC, Albany, New York, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03451890
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03451110
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03440424
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States